Use of ventricular assist devices in patients with mitral valve prostheses

Ayumi Goda, Hiroo Takayama, Michael Koeckert, Sang Woo Pak, Evelyne M. Sutton, Sara Cohen, Nir Uriel, Ulrich P. Jorde, Donna Mancini, Yoshifumi Naka

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Use of ventricular assist devices (VADs) in patients with prosthetic valves may carry an increased risk of thromboembolism; however, clinical information is lacking. The aim of this study was to report our experience of the use of VADs in patients with prosthetic mitral valves. Methods: A retrospective analysis of 747 VAD patients from January 1995 to May 2010 was performed. Results: Thirteen patients with a prosthetic mitral valve (average age 56 ± 10 years of age, nine mechanical valve, four biological valve) were identified. Indications for VAD implantation were as a bridge to transplant in 11 patients and destination therapy in two patients. At the time of VAD implant, no intervention to the prosthetic mitral valve was performed. Eight patients received a HeartMate I (Thoratec Corporation, Pleasanton, CA, USA), three patients received a HeartMate II (Thoratec Corporation), and two patients received a Thoratec VAD (Thoratec Corporation). Among nine mechanical valve patients, six patients were anticoagulated with warfarin, and one patient with heparin, while two patients did not receive anticoagulation due to bleeding. Ten patients were successfully transplanted at an average of 123 days post-VAD implant, one died after 48 days from multiorgan failure, and two remained on VAD support. No clinical thromboembolic events were observed. No intracardiac thrombus was detected by echocardiogram or on the pathology of the explanted hearts. Five patients had experienced a bleeding event (postoperative mediastinal bleeds, gastrointestinal bleedings, retroperitoneal hematoma, and subconjuctival bleeding). Conclusions: In patients with mitral valve prostheses who require VAD support, leaving the prosthesis intact does not increase the incidence of adverse events.

Original languageEnglish (US)
Pages (from-to)334-337
Number of pages4
JournalJournal of Cardiac Surgery
Volume26
Issue number3
DOIs
StatePublished - May 2011
Externally publishedYes

Fingerprint

Heart-Assist Devices
Mitral Valve
Prostheses and Implants
Hemorrhage
Thromboembolism
Warfarin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Goda, A., Takayama, H., Koeckert, M., Pak, S. W., Sutton, E. M., Cohen, S., ... Naka, Y. (2011). Use of ventricular assist devices in patients with mitral valve prostheses. Journal of Cardiac Surgery, 26(3), 334-337. https://doi.org/10.1111/j.1540-8191.2011.01248.x

Use of ventricular assist devices in patients with mitral valve prostheses. / Goda, Ayumi; Takayama, Hiroo; Koeckert, Michael; Pak, Sang Woo; Sutton, Evelyne M.; Cohen, Sara; Uriel, Nir; Jorde, Ulrich P.; Mancini, Donna; Naka, Yoshifumi.

In: Journal of Cardiac Surgery, Vol. 26, No. 3, 05.2011, p. 334-337.

Research output: Contribution to journalArticle

Goda, A, Takayama, H, Koeckert, M, Pak, SW, Sutton, EM, Cohen, S, Uriel, N, Jorde, UP, Mancini, D & Naka, Y 2011, 'Use of ventricular assist devices in patients with mitral valve prostheses', Journal of Cardiac Surgery, vol. 26, no. 3, pp. 334-337. https://doi.org/10.1111/j.1540-8191.2011.01248.x
Goda, Ayumi ; Takayama, Hiroo ; Koeckert, Michael ; Pak, Sang Woo ; Sutton, Evelyne M. ; Cohen, Sara ; Uriel, Nir ; Jorde, Ulrich P. ; Mancini, Donna ; Naka, Yoshifumi. / Use of ventricular assist devices in patients with mitral valve prostheses. In: Journal of Cardiac Surgery. 2011 ; Vol. 26, No. 3. pp. 334-337.
@article{b44d8a2b1b2e47c3a72dc8d2803f779d,
title = "Use of ventricular assist devices in patients with mitral valve prostheses",
abstract = "Background: Use of ventricular assist devices (VADs) in patients with prosthetic valves may carry an increased risk of thromboembolism; however, clinical information is lacking. The aim of this study was to report our experience of the use of VADs in patients with prosthetic mitral valves. Methods: A retrospective analysis of 747 VAD patients from January 1995 to May 2010 was performed. Results: Thirteen patients with a prosthetic mitral valve (average age 56 {\^A}± 10 years of age, nine mechanical valve, four biological valve) were identified. Indications for VAD implantation were as a bridge to transplant in 11 patients and destination therapy in two patients. At the time of VAD implant, no intervention to the prosthetic mitral valve was performed. Eight patients received a HeartMate I (Thoratec Corporation, Pleasanton, CA, USA), three patients received a HeartMate II (Thoratec Corporation), and two patients received a Thoratec VAD (Thoratec Corporation). Among nine mechanical valve patients, six patients were anticoagulated with warfarin, and one patient with heparin, while two patients did not receive anticoagulation due to bleeding. Ten patients were successfully transplanted at an average of 123 days post-VAD implant, one died after 48 days from multiorgan failure, and two remained on VAD support. No clinical thromboembolic events were observed. No intracardiac thrombus was detected by echocardiogram or on the pathology of the explanted hearts. Five patients had experienced a bleeding event (postoperative mediastinal bleeds, gastrointestinal bleedings, retroperitoneal hematoma, and subconjuctival bleeding). Conclusions: In patients with mitral valve prostheses who require VAD support, leaving the prosthesis intact does not increase the incidence of adverse events.",
author = "Ayumi Goda and Hiroo Takayama and Michael Koeckert and Pak, {Sang Woo} and Sutton, {Evelyne M.} and Sara Cohen and Nir Uriel and Jorde, {Ulrich P.} and Donna Mancini and Yoshifumi Naka",
year = "2011",
month = "5",
doi = "10.1111/j.1540-8191.2011.01248.x",
language = "English (US)",
volume = "26",
pages = "334--337",
journal = "Journal of Cardiac Surgery",
issn = "0886-0440",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Use of ventricular assist devices in patients with mitral valve prostheses

AU - Goda, Ayumi

AU - Takayama, Hiroo

AU - Koeckert, Michael

AU - Pak, Sang Woo

AU - Sutton, Evelyne M.

AU - Cohen, Sara

AU - Uriel, Nir

AU - Jorde, Ulrich P.

AU - Mancini, Donna

AU - Naka, Yoshifumi

PY - 2011/5

Y1 - 2011/5

N2 - Background: Use of ventricular assist devices (VADs) in patients with prosthetic valves may carry an increased risk of thromboembolism; however, clinical information is lacking. The aim of this study was to report our experience of the use of VADs in patients with prosthetic mitral valves. Methods: A retrospective analysis of 747 VAD patients from January 1995 to May 2010 was performed. Results: Thirteen patients with a prosthetic mitral valve (average age 56 ± 10 years of age, nine mechanical valve, four biological valve) were identified. Indications for VAD implantation were as a bridge to transplant in 11 patients and destination therapy in two patients. At the time of VAD implant, no intervention to the prosthetic mitral valve was performed. Eight patients received a HeartMate I (Thoratec Corporation, Pleasanton, CA, USA), three patients received a HeartMate II (Thoratec Corporation), and two patients received a Thoratec VAD (Thoratec Corporation). Among nine mechanical valve patients, six patients were anticoagulated with warfarin, and one patient with heparin, while two patients did not receive anticoagulation due to bleeding. Ten patients were successfully transplanted at an average of 123 days post-VAD implant, one died after 48 days from multiorgan failure, and two remained on VAD support. No clinical thromboembolic events were observed. No intracardiac thrombus was detected by echocardiogram or on the pathology of the explanted hearts. Five patients had experienced a bleeding event (postoperative mediastinal bleeds, gastrointestinal bleedings, retroperitoneal hematoma, and subconjuctival bleeding). Conclusions: In patients with mitral valve prostheses who require VAD support, leaving the prosthesis intact does not increase the incidence of adverse events.

AB - Background: Use of ventricular assist devices (VADs) in patients with prosthetic valves may carry an increased risk of thromboembolism; however, clinical information is lacking. The aim of this study was to report our experience of the use of VADs in patients with prosthetic mitral valves. Methods: A retrospective analysis of 747 VAD patients from January 1995 to May 2010 was performed. Results: Thirteen patients with a prosthetic mitral valve (average age 56 ± 10 years of age, nine mechanical valve, four biological valve) were identified. Indications for VAD implantation were as a bridge to transplant in 11 patients and destination therapy in two patients. At the time of VAD implant, no intervention to the prosthetic mitral valve was performed. Eight patients received a HeartMate I (Thoratec Corporation, Pleasanton, CA, USA), three patients received a HeartMate II (Thoratec Corporation), and two patients received a Thoratec VAD (Thoratec Corporation). Among nine mechanical valve patients, six patients were anticoagulated with warfarin, and one patient with heparin, while two patients did not receive anticoagulation due to bleeding. Ten patients were successfully transplanted at an average of 123 days post-VAD implant, one died after 48 days from multiorgan failure, and two remained on VAD support. No clinical thromboembolic events were observed. No intracardiac thrombus was detected by echocardiogram or on the pathology of the explanted hearts. Five patients had experienced a bleeding event (postoperative mediastinal bleeds, gastrointestinal bleedings, retroperitoneal hematoma, and subconjuctival bleeding). Conclusions: In patients with mitral valve prostheses who require VAD support, leaving the prosthesis intact does not increase the incidence of adverse events.

UR - http://www.scopus.com/inward/record.url?scp=79957511436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957511436&partnerID=8YFLogxK

U2 - 10.1111/j.1540-8191.2011.01248.x

DO - 10.1111/j.1540-8191.2011.01248.x

M3 - Article

C2 - 21480991

AN - SCOPUS:79957511436

VL - 26

SP - 334

EP - 337

JO - Journal of Cardiac Surgery

JF - Journal of Cardiac Surgery

SN - 0886-0440

IS - 3

ER -